Stock Research for ABSCF

Current Price


Latest Update: 2018-03-14 09:51:00

$ 12.1000
$ 12.1000
$ 12.1000

Featured Broker: TradeStation

Get the due diligence for another stock.


ABSCF Stock Chart & Research Data

The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ABSCF Due diligence Resources & Stock Charts

The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABSCF Detailed Price Forecast - CNN Money CNN View ABSCF Detailed Summary - Google Finance
Yahoo View ABSCF Detailed Summary - Yahoo! Finance Zacks View ABSCF Stock Research & Analysis -

Stock Analysis

TradeIdeas View ABSCF Trends & Analysis - Trade-Ideas Barrons View ABSCF Major Holders - Barrons
NASDAQ View ABSCF Call Transcripts - NASDAQ Seeking View ABSCF Breaking News & Analysis - Seeking Alpha
Spotlight View ABSCF Annual Report - OTC Report View ABSCF OTC Short Report -
TradeKing View ABSCF Fundamentals - TradeKing Charts View ABSCF SEC Filings - Bar Chart
WSJ View Historical Prices for ABSCF - The WSJ Morningstar View Performance/Total Return for ABSCF - Morningstar
MarketWatch View the Analyst Estimates for ABSCF - MarketWatch CNBC View the Earnings History for ABSCF - CNBC
StockMarketWatch View the ABSCF Earnings - StockMarketWatch MacroAxis View ABSCF Buy or Sell Recommendations - MacroAxis
Bullish View the ABSCF Bullish Patterns - American Bulls Short Pains View ABSCF Short Pain Metrics -

Social Media Mentions

StockTwits View ABSCF Stock Mentions - StockTwits PennyStocks View ABSCF Stock Mentions - PennyStockTweets
Twitter View ABSCF Stock Mentions - Twitter Invest Hub View ABSCF Investment Forum News - Investor Hub
Yahoo View ABSCF Stock Mentions - Yahoo! Message Board Seeking Alpha View ABSCF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ABSCF - Insider Cow View Insider Transactions for ABSCF - Insider Cow
CNBC View ABSCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABSCF - OTC Markets
Yahoo View Insider Transactions for ABSCF - Yahoo! Finance NASDAQ View Institutional Holdings for ABSCF - NASDAQ

Stock Charts

FinViz View ABSCF Stock Insight & Charts - StockCharts View ABSCF Investment Charts -
BarChart View ABSCF Stock Overview & Charts - BarChart Trading View View ABSCF User Generated Charts - Trading View

Latest Financial News for ABSCF

Is AB Science SA. (EPA:AB) A Financially Sound Company?
Posted on Monday March 12, 2018

Investors are always looking for growth in small-cap stocks like AB Science SA. (ENXTPA:AB), with a market cap of €337.59M. However, an important fact which most ignore is: how financiallyRead More...

AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to increase the sample size
Posted on Thursday January 04, 2018

Paris, January 4 2018, 5.45 pm. AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no ...

AB Science announces the publication of Preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments
Posted on Tuesday November 21, 2017

Paris, 21 November 2017, 5.45pm Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine Phase 3 clinical ...

AB Science reports its revenue for the first half of 2017
Posted on Thursday August 31, 2017

Paris, August 31 2017, 6pm Net loss of 13.5M€ in the first half of 2017, a decrease of 8.4% as compared with the first half of 2016 (14.7M€), due to R&D costs decrease Cash position of 49.3M€ as of 30 ...

Warning: DOMDocument::load(): StartTag: invalid element name in, line: 1 in /home/allsites/ on line 494

Warning: DOMDocument::load(): Extra content at the end of the document in, line: 1 in /home/allsites/ on line 494

Enter a stock symbol to view the stock details.